Effects of Ferric Derisomaltose in Heart Failure with Iron Deficiency according to Renal Function in the IRONMAN Randomised Controlled Trial.

ABSTRACT:

Introduction

For heart failure (HF) with iron deficiency (ID), the benefits of intravenous iron might differ according to kidney function.

Methods

IRONMAN was a randomised, open-label trial of intravenous ferric derisomaltose (FDI) versus usual care (UC) in patients with HF, left ventricular ejection fraction ≤45%, and ID (transferrin saturation <20% and/or ferritin <100 µg/L). The primary composite endpoint of recurrent hospitalisation for HF and cardiovascular (CV) death was lower in those assigned to FDI. Analysis according to baseline estimated glomerular filtration rate (eGFR) is now reported, with outcomes assessed in 3 categories of eGFR.

Results

Of 1,137 patients randomised, eGFR was <45 mL/min/1.73 m2 for 435 (38%), 45-59 mL/min/1.73 m2 for 295 (26%), and ≥60

SUBMITTER: Ahmed FZ 

PROVIDER: S-EPMC12503502 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature